Trevi Therapeutics Inc (TRVI) concluded trading on Thursday at a closing price of $7.84, with 3.8 million shares of worth about $29.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 107.41% during that period and on July 24, 2025 the price saw a loss of about -0.63%. Currently the company’s common shares owned by public are about 99.89M shares, out of which, 69.87M shares are available for trading.
Stock saw a price change of 14.62% in past 5 days and over the past one month there was a price change of 35.88%. Year-to-date (YTD), TRVI shares are showing a performance of 179.00% which increased to 90.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.36 but also hit the highest price of $8.11 during that period. The average intraday trading volume for Trevi Therapeutics Inc shares is 1.84 million. The stock is currently trading 21.41% above its 20-day simple moving average (SMA20), while that difference is up 23.66% for SMA50 and it goes to 60.02% higher than SMA200.
Trevi Therapeutics Inc (NASDAQ: TRVI) currently have 99.89M outstanding shares and institutions hold larger chunk of about 47.39% of that.
The stock has a current market capitalization of $934.09M and its 3Y-monthly beta is at 0.61. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 15.38 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TRVI, volatility over the week remained 7.17% while standing at 5.91% over the month.
Stock’s fiscal year EPS is expected to rise by 8.52% while it is estimated to decrease by -26.05% in next year. EPS is likely to shrink at an annualized rate of -12.29% for next 5-years, compared to annual growth of 27.09% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on July 01, 2025 offering an Overweight rating for the stock and assigned a target price of $25 to it. Coverage by H.C. Wainwright stated Trevi Therapeutics Inc (TRVI) stock as a Buy in their note to investors on May 28, 2025, suggesting a price target of $21 for the stock. On March 10, 2025, Raymond James Upgrade their recommendations, while on March 10, 2025, Needham Reiterated their ratings for the stock with a price target of $25. Stock get a Buy rating from H.C. Wainwright on December 12, 2024.
